TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17053340
Drug: Self-exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-exposure therapy (4 weeks)
Study: 8458248
Drug: Ceftriaxone (CFX)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone (CFX) plus amikacin (single daily doses)
Study: 8458248
Drug: Ceftriaxone (CFX)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone (CFX) plus amikacin (divided in three doses)
Study: 31464063
Drug: Faster insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faster insulin aspart
Study: 31464063
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin aspart
Study: 11243631
Drug: Anti-CD3 antibodies
Normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD3 antibodies (1 microg/ml)
Study: 11243631
Drug: Phytohemagglutinin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytohemagglutinin (10 microg/ml)
Study: 11243631
Drug: Staphylococcal enterotoxin
Normalized name: Staphylococcal enterotoxin B specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staphylococcal enterotoxin A (0.1 microg/ml)
Study: 11243631
Drug: Tuberculin purified
Normalized name: Tuberculin Purified Protein Derivative
DrugBank: Tuberculin purified protein derivative (DB11601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculin purified protein derivative (10 microg/ml)
Study: 8455962
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of pethidine
Study: 3513569
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (10 mg/day) for 4 months
Study: 3513569
Drug: Control medications
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control medications
Study: 3513569
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid treatment
Study: 24351527
Drug: Standard VTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard VTE prophylaxis (5,000 U low‐molecular‐weight heparin daily)
Study: 24351527
Drug: TEG‐guided prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEG‐guided prophylaxis (up to 10,000 U low‐molecular‐weight heparin daily)
Study: 16176140
Drug: Cassia tora
Normalized name: Padang cassia oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cassia tora fiber supplement (2 g of soluble fiber, 200 mg of alpha-tocopherol, 500 mg of ascorbic acid, 300 mg of maltodextrin)
Study: 16176140
Drug: Cassia tora
Normalized name: Padang cassia oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cassia tora fiber supplement
Study: 8690639
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Radiotherapy + Hyperthermia)
Study: 7120436
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control conditions
Study: 22662729
Drug: Telehealth intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telehealth intervention for self-care management; specific details on dosage and duration not available.
Study: 22662729
Drug: Telecommunications technologies;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telecommunications technologies; specific details on dosage and duration not available.
Study: 12135250
Drug: IAS pacing
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAS pacing in AAIR mode plus antiarrhythmic drugs
Study: 12135250
Drug: IAS pacing
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAS pacing in AAIR mode without antiarrhythmic drugs
Study: 12135250
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (before pacemaker implantation, under antiarrhythmic treatment)
Study: 12135250
Drug: AAIR pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAIR pacing mode without antiarrhythmic drugs
Study: 10025887
Drug: E. coli
Normalized name: E. coli antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. coli L-asparaginase at 10,000 IU/m2 thrice weekly for nine doses
Study: 10025887
Drug: Epidoxorubicin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidoxorubicin at 20 mg/m2 weekly for two doses
Study: 7862469
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15 to 20 micrograms/kg
Study: 2031199
Drug: Vindesin 3
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesin 3 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 600 mg/m2 + lonidamine 600 mg/day orally
Study: 2031199
Drug: Vindesin 3
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesin 3 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 600 mg/m2
Study: 21558074
Drug: Bevacizumab-based therapy
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab-based therapy
Study: 19247267
Drug: perindopril/indapamide (2/0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril/indapamide (2/0.625 mg, daily)
Study: 19247267
Drug: atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50 mg, daily)
Study: 15145099
Drug: Intravenous beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous beta-blockers before PCI (BB+ group)
Study: 15145099
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous beta-blockers before PCI (BB- group)
Study: 11187220
Drug: Mivacurium (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (bolus dose 0.15 mg/kg followed by continuous infusion)
Study: 11187220
Drug: Atracurium (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (bolus dose 0.4 mg/kg followed by continuous infusion)
Study: 3910053
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (G.B.E.) 3 X 40 mg/day
Study: 3910053
Drug: Nicergoline 5
Normalized name: nicergoline 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline 5 mg
Study: 27099272
Drug: 150 min/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 min/wk of aerobic exercise (low dose)
Study: 21409296
Drug: Standard self-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard self-administration of ART
Study: 16503844
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) with free patches and intensive instructions from nurses
Study: 11059180
Drug: High-chilli diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-chilli diet (approximately 15 g/day) for 3 days.
Study: 8792944
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 750 mg bid after 72 hours of intravenous antibiotics (group 1)
Study: 8792944
Drug: Parenteral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral therapy alone (group 2)
Study: 8792944
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (group 1)
Study: 1298468
Drug: Danggui Funing
Normalized name: FUNEES KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danggui Funing (DGFN) pill
Study: 30907929
Drug: Superpower Glass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superpower Glass intervention plus standard of care applied behavioral analysis therapy
Study: 30907929
Drug: Applied behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied behavioral analysis therapy (control)
Study: 26401577
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate (K-citrate), 40 mEq daily for 1 year
Study: 21410944
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dose of methotrexate/day for 5 days
Study: 21410944
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dose of methotrexate
Study: 17347500
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg orally) along with conventional opioid treatment
Study: 17347500
Drug: Conventional opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional opioid treatment
Study: 14687524
Drug: NO inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO inhalation of 10 ppm
Study: 10516936
Drug: Controlled-delivery formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-delivery formulation of 240 mg diltiazem (DIL)
Study: 10516936
Drug: Extended-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release formulation of 10 mg felodipine (FEL)
Study: 10516936
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg amlodipine (AML)
Study: 1968329
Drug: Good therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good therapeutic alliance with therapists within the first 6 months of treatment
Study: 7423602
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of ascorbic acid as one effervescent tablet once daily
Study: 24443174
Drug: Annual low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Annual low-dose CT screening (CT group)
Study: 20692602
Drug: Lactoferrin-enriched fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin-enriched fermented milk (200 mg of lactoferrin daily)
Study: 10353670
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion of 50 mg/kg tranexamic acid at the end of cardiopulmonary bypass (control group)
Study: 10353670
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion of 50 mg/kg tranexamic acid at the beginning of cardiopulmonary bypass (group A)
Study: 10353670
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion of 50 mg/kg tranexamic acid at the beginning of cardiopulmonary bypass and continuous infusion of 10 mg/kg per h for 6 h after cardiopulmonary bypass (group B)
Study: 8745671
Drug: Concomitant radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant radiotherapy with cisplatin (CDDP) 20 mg/m2, 5-fluorouracil (5-FU) 400 mg/m2 (day 1 to day 4), and mitomycin C (MMC) 10 mg/m2 (day 1) for three cycles at days 1, 21, and 42.
Study: 7028084
Drug: 1% chlortetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlortetracycline eye ointment
Study: 7028084
Drug: 1% rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% rifampicin eye ointment
Study: 28826645
Drug: Oral ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketorolac 20 mg
Study: 23998970
Drug: Morning-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning-dose group (20 mg controlled-release simvastatin in the morning, placebo in the evening)
Study: 23998970
Drug: Evening-dose group
Normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evening-dose group (placebo in the morning, 20 mg controlled-release simvastatin in the evening)
Study: 21832863
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray 0.1% (ANS)
Study: 21832863
Drug: Levocabastine nasal
Normalized name: levocabastine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine nasal spray 0.05% (LNS)
Study: 9063764
Drug: 1,500 mg
Normalized name: garlic 1,500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg L-arginine and 1,500 mg L-lysine ingestion followed by resistance exercise (Trial B)
Study: 9063764
Drug: 1,500 mg
Normalized name: garlic 1,500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg L-arginine and 1,500 mg L-lysine ingestion without exercise (Trial C)
Study: 3101535
Drug: Ro 15-1788
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15-1788 (0.5 to 2.0 mg)
Study: 3101535
Drug: Ro 15-1788
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15-1788 (0.3 to 0.8 mg)
Study: 30455091
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy interventions (manual therapy and exercise)
Study: 30455091
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy and trigger point dry needling
Study: 30455091
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy and sham trigger point dry needling
Study: 26995298
Drug: Escitalopram, Sertraline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, Sertraline, or Venlafaxine extended-release (8 weeks treatment)
Study: 26995298
Drug: Matched healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched healthy participants (no medication or intervention)
Study: 25498992
Drug: Home telemonitoring
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home telemonitoring (n=47); patients measured body weight, blood pressure, pulse, and answered symptom-related questions weekly, reporting to a heart failure nurse via a mobile app.
Study: 25498992
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=47); received multidisciplinary treatment according to standard practices.
Study: 22749594
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal polysaccharide vaccine and/or 7-valent pneumococcal conjugate vaccine (PCV7)
Study: 20031392
Drug: Oral clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clodronate 1600 mg/d
Study: 10864113
Drug: Hot, humid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot, humid air inhaled in a chamber
Study: 3878719
Drug: Propofol (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (with lignocaine 0.5 mg)
Study: 28704328
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) alone (20 mg IV)
Study: 28704328
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) plus Hydrocortisone (HCT) (100 mg IV)
Study: 25341431
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment, 30-min weekly for 3 weeks
Study: 16391584
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg (600 IU) vitamin D(3) and 1,500 mg calcium/day for 8 weeks
Study: 16391584
Drug: 1,500 mg
Normalized name: garlic 1,500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg calcium/day for 8 weeks (control group)
Study: 15292721
Drug: Acupressure on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure on P6 point (Nei-Guan) for 5 minutes at least 3 times a day before chemotherapy and mealtimes
Study: 15292721
Drug: Regular antiemesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular antiemesis medication (Control group)
Study: 11441413
Drug: 100 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/m2 docetaxel for three cycles before definitive surgery or radiotherapy
Study: 11441413
Drug: Neoadjuvant docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant docetaxel in combination with cisplatin or carboplatin
Study: 9158047
Drug: Pentoxifylline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (20 mg/kg/day intravenously in 150 ml of saline for five days)
Study: 9158047
Drug: Placebo (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (150 ml of saline without POF)
Study: 8198036
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg plus hydrochlorothiazide 12.5 mg (group 2)
Study: 8198036
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg (group 1)
Study: 2195345
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine (100 mg/ml, 5 ml, three times daily)
Study: 31919134
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (taxane and anthracycline)
Study: 31919134
Drug: Residual cancer
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual cancer after neoadjuvant chemotherapy
Study: 30850828
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 100 mg MEF/kg diet
Study: 30850828
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 300 mg ECOS/kg diet
Study: 30850828
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 100 mg MEF/kg diet + 300 mg ECOS/kg diet
Study: 30850828
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 500 mg ECOS/kg diet
Study: 30850828
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 100 mg MEF/kg diet + 500 mg ECOS/kg diet
Study: 28052513
Drug: Problem Solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Solving Therapy (PST, n = 10)
Study: 21707926
Drug: Gepirone-ER (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone-ER (40-80 mg/day)
Study: 19486255
Drug: TACE-IFN (interferon-alpha1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE-IFN (interferon-alpha1b at a dose of 3 million units three times a week for 48 weeks)
Study: 11579890
Drug: Atovaquone-proguanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone-proguanil (1 tablet daily for 7 days)
Study: 7880659
Drug: Clonidine 5
Normalized name: apraclonidine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 5 micrograms kg‐1 and famotidine 20 mg (n = 20)
Study: 7880659
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (famotidine 20 mg) (n = 20)
Study: 2835200
Drug: Conventional prazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional prazosin (2 mg)
Study: 2835200
Drug: Oros prazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oros prazosin (5.5 mg)
Study: 29909377
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 or 100 mg daily)
Study: 27041480
Drug: Candesartan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day
Study: 23735519
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride (200 to 400mg daily for 4 weeks)
Study: 23735519
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 4 weeks)
Study: 18670333
Drug: Cervical medial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical medial branch blocks with bupivacaine and steroid (steroid group)
Study: 12941993
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined angiotensin-converting enzyme inhibitor and calcium channel blocker antihypertensive treatment
Study: 12941993
Drug: Two preselected,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two preselected, fixed-dose combination therapies
Study: 9215092
Drug: Aciclovir 200
Normalized name: Aciclovir 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir 200 mg five times daily
Study: 8203335
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg three times daily
Study: 3311120
Drug: Codeine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (30 mg four times daily)
Study: 3311120
Drug: Promethazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (25 mg four times daily)
Study: 25864939
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg single dose)
Study: 21266929
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg·kg(‐1))
Study: 9624028
Drug: Short-acting antibiotics
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting antibiotics for 5 days
Study: 9624028
Drug: Short-acting antibiotics
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting antibiotics for 8 to 10 days
Study: 9624028
Drug: Long course
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course of short-acting antibiotics
Study: 9624028
Drug: Short-acting antibiotics
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting antibiotics
Study: 7911624
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide monotherapy
Study: 7911624
Drug: Hydrocolloid dressing
Normalized name: hydrocolloid dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid dressing monotherapy
Study: 31536837
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of TXA for every 1000 mL of the distending medium